Todd K. Macklin Ph.D. is a registered patent agent in the patent counseling and prosecution practice of Dechert’s intellectual property group. Dr. Macklin focuses his practice on chemical and pharmaceutical intellectual property matters, including the drafting and prosecution of patent applications before the U.S. Patent and Trademark Office and foreign patent offices. He advises clients on patent portfolio management strategies and provides evaluations and opinions on patentability, freedom-to-operate, clearance and transactional due diligence.
Dr. Macklin also has experience in several phases of Hatch-Waxman and patent infringement litigation matters involving small molecule and immuno-oncology therapeutics. He assists clients with pre-suit analysis and strategy, discovery, claim construction, and the preparation of invalidity and non-infringement contentions, as well as expert reports.
Prior to joining Dechert, Dr. Macklin worked at two global law firms as a patent agent in patent prosecution and as a scientific advisor in patent litigation. Before practicing law, he worked as a medicinal chemist in the pharmaceutical industry developing small molecule CNS therapeutics for the treatment of neurological disorders. This work resulted in Dr. Macklin being a co-inventor on several patent families, leading to a US$140 million start-up pharmaceutical acquisition. His academic tenure included postdoctoral research at Yale University and The Scripps Research Institute where his research in total synthesis and synthetic methodologies has been published in numerous top chemistry journals, including Nature Chemistry, Journal of the American Chemical Society and Angewandte Chemie.